MDMA THERAPY

Attention to psychedelics in healthcare is growing, and with it the question of whether substances like psilocybin can offer any help with persistent complaints such as migraines. In early 2026, a small, exploratory clinical study was published that investigated precisely this: can psilocybin help prevent migraine attacks, and what is the role of placebo and expectations in this? In this article, we outline the key findings, explain how best to interpret these types of results, and place them in the broader context of therapy, safety, and research.

What exactly was investigated?

The study in question is titled: “Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial” (Schindler et al.). It involved a randomized, double-blind, placebo-controlled parallel-group study in adults with migraine. At the start, participants had an average of at least two migraine days per week. A total of 18 people participated, which is immediately important for the interpretation: this is a small study, intended to explore signals, not to draw definitive conclusions.

The participants received two sessions. There were three groups: one group received an active placebo (diphenhydramine) twice, a second group received psilocybin and diphenhydramine once, and a third group received psilocybin twice. The psilocybin dose was 10 mg per session. The active placebo was 25 mg diphenhydramine. The primary outcome measure was the change in migraine frequency based on a headache diary, measured from two weeks before to eight weeks after the second session.

The results: an interesting signal, not hard evidence

In the first two weeks after completion of the sessions, the difference between the three groups in the reduction of migraine days per week was not statistically significant. The decrease averaged approximately -0.7 (placebo-placebo), -2.0 (placebo-psilocybin), and -1.7 (psilocybin-psilocybin), with p = 0.102. This means: based on these data, it cannot be stated with sufficient certainty that psilocybin works better than the active placebo.

At the same time, the authors did observe relatively large effect sizes compared to placebo, particularly in the group that received a single dose of psilocybin. Over the entire eight-week measurement period, migraine frequency decreased by approximately 50% in all groups. This is notable, as it demonstrates how strong non-specific effects can be in this type of research: study participation, attention, monitoring, and expectations can all contribute to improvement.

The so-called “50% responder rate” was also examined: the number of people who saw their migraine frequency decrease with at least 50% over the first two weeks. This was 17% in the placebo group and 80% in both psilocybin groups, but this result also just failed to reach statistical significance (p = 0.087). In a larger study, such a difference might potentially become more convincing, but that is currently uncertain.

Why the dose and schedule matter

A striking detail is that one dose of psilocybin appeared numerically better than two doses. This does not automatically fit with the intuition that “more” or “more often” is also “better.” However, in a small sample, such a pattern could also be coincidental. For example, it could arise because a few participants in a group happened to react more strongly, or because there are differences in migraine patterns, expectations, or environmental factors.

In addition, 10 mg of psilocybin is relatively low compared to dosages used in some other therapeutic research contexts. The interpretation here is therefore cautious: if the dosage is too low, it may be more difficult to clearly distinguish a pharmacological effect from placebo effects and contextual effects. At the same time, a “higher dose” is not automatically “better” or “safer”: it can also lead to more intense acute effects, and consequently other risks or a greater need for supervision.

Active placebo, blinding, and expectations: crucial with psychedelics

Research with psychedelics presents an additional challenge: many participants typically notice whether they have been given a psychedelic substance, which can cause blinding to leak. If someone (consciously or unconsciously) thinks, “I have the real drug,” expectations and hope can play a stronger role in the perceived improvement. This makes it more difficult to determine which part of the effect is truly pharmacological.

To make the blinding more credible, this study used diphenhydramine as the active placebo. While this can induce drowsiness and physical sensations, thereby mimicking part of the “something is happening” feeling, it does not appear to approximate the full experience. The researchers concluded that diphenhydramine partially mimicked the acute effects of psilocybin, but not completely.

Interestingly, the authors found no clear correlation between migraine improvement after psilocybin and factors such as “drug confidence” (how certain someone was of what they had received), general acute drug effects, or acute psychedelic effects. This may indicate that the mechanism is not simply “the stronger the trip, the better the effect.” But here too, the same applies: with 18 participants, it is difficult to find robust connections.

What does this mean for therapy in practice?

This study is primarily encouraging as a signal, not as proof. It shows that further research into psilocybin for migraine may be worth investigating, but also that it is methodologically challenging due to placebo effects, expectation bias, and blinding. The idea that psilocybin might play a role as a “transitional preventive treatment” is suggested by the data, but cannot yet be firmly substantiated.

When it comes to therapy with psychedelics, it is also important to distinguish between (1) scientific research, (2) anecdotal evidence and (3) practical harm reduction information. Anecdotal evidence can be valuable for understanding what people are going through, but it is not proof that a treatment works. Clinical studies specifically try to measure the difference between drug effects and non-drug effects, and this has not yet been convincingly achieved here.

Safety remains a central theme in this regard. Psychedelics can temporarily and strongly influence the experience. Setting, preparation, guidance, and aftercare are factors that are often carefully designed in research. Outside of research, this is not a given, and risks can play out differently. Moreover, in the Netherlands, psilocybin in “truffle form” is approached differently in some contexts than pure psilocybin in studies, meaning that research results cannot be directly translated to what people outside of a study would do or experience.

Practical harm reduction: what you can and cannot conclude

What you can say based on this study is that there is an interesting signal that psilocybin may be associated with a decrease in migraine frequency, and the study underscores how significant the influence of placebo and context can be. It is also positive that no serious or unexpected side effects were reported, although with 18 participants, that says little about rare risks.

What you cannot say: that psilocybin is “proven” to help with migraines, which dose is “best,” or that you can use it safely and effectively on your own. For that, much more research is needed with larger groups, better blinding, and likely multiple dosing strategies.

Anyone exploring psychedelics and therapy more broadly would do well to pay particular attention to the quality of the evidence, the study design, and the role of set and setting. You can read the original overview of this study, with attention to placebo and blinding, via Psilocybin in migraine: study on effect and placebo influence.

Brief conclusion

This exploratory trial with 18 participants provides an encouraging signal that psilocybin may be relevant in migraine prevention, but does not yet provide convincing evidence that it works better than an active placebo. In particular, the role of expectations, placebo effects, and incomplete blinding appears to determine how the outcomes should be interpreted. Follow-up studies with larger groups and more careful designs are needed to better distinguish between drug effects and contextual effects.

For those exploring therapy with psychoactive substances, it is important to know that MDMA sessions can currently only be discussed and approached within the framework of scientific research or in practice via harm reduction. If you wish to register for a carefully supervised program within these frameworks, you can find more information via sign up for an MDMA session.